Shanghai Pharmaceuticals Sets Board Line-up and Committee Roles

Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has issued an announcement.

Shanghai Pharmaceuticals Holding Co., Ltd. has announced the updated composition of its board of directors as of 11 February 2026, naming Yang Qiuhua as chairman alongside three other executive directors, one non-executive director, one employee director and four independent non-executive directors. The disclosure also details the membership and conveners of its strategy, nomination, audit, and remuneration and assessment committees, underscoring the company’s governance structure and oversight framework for strategic planning, risk control and senior management incentives.

The refreshed committee line-up, including independent directors in key oversight roles such as the audit and nomination committees, is designed to enhance corporate governance and transparency for shareholders and other stakeholders. By clearly delineating responsibilities among directors and committee conveners, the company signals continued emphasis on compliance, board independence and structured decision-making as it manages its pharmaceutical operations and long-term strategic objectives.

The most recent analyst rating on (HK:2607) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.

More about Shanghai Pharmaceuticals Holding Co

Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group engaged in the manufacture, distribution and retail of medicines and healthcare products. Listed in Hong Kong under stock code 02607, the company operates across the pharmaceutical value chain with a focus on the domestic market and institutional and retail customers in the healthcare sector.

Average Trading Volume: 2,427,914

Technical Sentiment Signal: Buy

Current Market Cap: HK$65.06B

For an in-depth examination of 2607 stock, go to TipRanks’ Overview page.